Literature DB >> 26560323

An Overview of Current Screening and Management Approaches for Prostate Cancer.

Omar N Akram, Gohar Mushtaq, Mohammad Amjad Kamal1.   

Abstract

Prostate cancer is the fourth leading cause of mortality in Australian men. The prevalence and incidence is increasing in both developed and developing nations, thus there is a need for better screening and management of this disorder. While there is no direct known cause of prostate cancer, management is largely focused on early detection and treatment strategies. Of particular concern is advanced prostate cancer which can manifest as castrate resistant prostate cancer characterized by therapy resistance. This short review outlines the global epidemiology of prostate cancer, clinical manifestations, risk factors, current screening strategies including first line clinical screening as well as the use of circulating biomarkers, and treatment of prostate cancer through mainstream therapeutics as well as the cutting edge peptide and nano-technology based therapeutics that are being implemented or in the process of development to overcome therapeutic obstacles in the treatment of prostate cancer.

Entities:  

Mesh:

Year:  2015        PMID: 26560323     DOI: 10.2174/1389200216666150812122430

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  2 in total

1.  Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials.

Authors:  Ja Hyeon Ku; Hyeon Hoe Kim; Minyong Kang; Chang Wook Jeong; Cheol Kwak
Journal:  Oncotarget       Date:  2017-05-10

2.  miR-1303 promotes the proliferation, migration and invasion of prostate cancer cells through regulating the Wnt/β-catenin pathway by targeting DKK3.

Authors:  Bo Liu; Weidong Zhou; Huiyang Jiang; Zhendong Xiang; Lei Wang
Journal:  Exp Ther Med       Date:  2019-10-23       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.